资源描述：
《肺腺癌患者血清生物标志物筛选探究》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。
1、肺腺癌患者血清生物标志物筛选探究【摘要】目的采用SELDI-TOF-MS技术探讨肺腺癌患者血清蛋白标志物，并建立一个稳定、简便、快速的实验方法。方法肺腺癌患者321例和正常对照人群321例，按照年龄、性别、吸烟史的有无进行1：1配对，采用WCX2芯片技术进行血清蛋白质组学研究，用蛋白芯片阅读器PBSII对芯片进行扫描、分析。结果肺腺癌患者血清蛋白图谱与正常对照组相比，存在15个差异表达蛋白（P<；10-5）,其中包括11个高表达蛋白，分子量分别是1860Da.4055%、4195Da.4211Da.4959D
2、a、5329Da.5980Da.6313Da.6880Da.7762Da、9281Da,4个低表达蛋白，分子量分别是2564Da、2932Da、3082Da、3442Dao显著高表达的潜在标志物5个，相对分子量分别为4055Da、421IDa、4959D&、5329Da和7762Da,以峰值比1.5为界值时，其诊断肺腺癌的灵敏度分别为90.41%,78.08%、50.68%、57.53%、72.60%,特异度分别为97.06%、93.44%.71.15%、76.36%、94.92%,选用4055Da.4211Da
3、.4959Da、5329Da和7762D&建立决策树模型对样品进行筛选验证，其准确率为85.00%,灵敏度为86.67%,特异度为83.33%o结论用该技术能筛选出灵敏度和特异性较好的差异表达蛋白，为肺腺癌的早期发现提供了一种新的、无创伤的实验方法，可能具有较好的临床应用前景。【关键词】肺腺癌；生物标志物；SELDI-TOF-MS；蛋白质组学ThescreeningstudyonlungadenocarcinomaserumbiomarkersbySELDI-TOF-MS[Abstract】ObjectiveTo
4、selectrelativespecificbiomarkersinserumfromlungadenocarcinomapatientsusingsurface-enhancedlaserdesorptionandionizationtimeofflightmassspectrometry(SELDI-TOF-MS)proteinchiptechnology.MethodsSerumsamplesfrom321lungadenocarcinomapatients,321healthyvolunteerswith
5、matchedgender,ageandhistoryofsmokingwereanalyzedusingWCX2poteinchiptoscreeningpotentiallybiomarkers・Proteomicspectraweregeneratedbymassspectrometry.ResultsFivehighlyexpressedpotentialbiomarkerswereidentifiedwiththerelativemolecularweightsof4055Da,421IDa,4959D
6、a,5329Daand7762Da.Thesensitivityfordiagnosinglungadenocarcinomawas90.41%，78.08%，50.68%,57.53%,72.60%；andspecificitywas97.06%,93.44%,71.15%,76.36%,94.92%,whenthecriticalpointwasmade1.5.Thesensitivityfordiagnosinglungadenocarcinomawas86.67%,andspecificitywas83.
7、33%byappliedtothisproteinfingerprintspatternvalidation・ConclusionSELDI-TOF-MSproteinchiptechnologyisaquick,easy,convenient,andhigh-throughputanalyzingmethodcapableofselectingseveralrelativelyspecific,potentialbiomarkersfromtheserumoflungadenocarcinomapatients
8、andmayhaveattractiveclinicvalue・[Keywords】lungadenocarcinoma；biomarkers；SELDI-TOF-MS；proteomics肺癌是目前全球发病率最高的恶性肿瘤之一，对人类健康的危害日益严重。目前，肺癌早期诊断困难。80%肺癌患者就诊时已属晚期，失去了手术根治的机会，放疗化疗效果不佳，5年生存率不到15%；而
